David Lillicrap

David Lillicrap’s research focuses on the molecular characterization of the most common inherited bleeding diseases, hemophilia and von Willebrand disease. His studies of hemophilia have developed and evaluated novel gene-based therapies for this classical recessive genetic trait. Additionally, he has contributed novel information concerning the immune response to factor VIII therapy, and how this response can be abrogated. His studies of von Willebrand disease have focused on understanding the genetic mechanisms underlying the pathology. Lillicrap’s research is leading to innovative strategies for the diagnosis and gene-based treatment of these inherited bleeding disorders and the enhanced quality of life for patients.